Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day
on November 5, 2026

NEW YORK, October 29, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it will host a virtual Research and Development (R&D) Day focused on progressive multiple sclerosis (MS) on Thursday, November 5, 2026, at 12:30 pm ET.

In addition to members of Immunic’s management team, including Erik Lundgren, M.B.A., Chief Executive Officer, Michael A. Panzara, M.D., M.P.H., Chief Medical Officer, Hella Kohlhof, Ph.D., Chief Scientific Officer, and Jason Tardio, M.B.A., President & Chief Operating Officer, the event will feature presentations by two renowned experts in the treatment of MS and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy.

The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Immunic management will highlight the potential expansion opportunity for lead investigational asset vidofludimus calcium (IMU-838) in progressive MS, including the clinical and scientific rationale supporting Immunic’s plans to initiate a Phase 3 progressive MS trial later in 2026. The differentiated profile of vidofludimus calcium, including its activity as a nuclear receptor-related 1 (Nurr1) activator and the potential neuroprotective effects associated with this mechanism, provides scientific rationale for its evaluation in progressive forms of MS.

The Virtual Progressive MS R&D Day will take place on Thursday, November 5, 2026, at 12:30 pm ET. To register for the event, please CLICK HERE.
 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory Phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com

• EU-GMP certification for craft cannabis producer: LOT420 is among the most sought-after suppliers in the European medical cannabis market.
• Shorter delivery times, fresher products: LOT420’s cannabis flowers will reach European pharmacies even faster in the future.
• Strategic competitive advantage: With the EU-GMP certification of another established premium producer, Cantourage strengthens its access to high-demand products and further consolidates its position in the European market.

Cantourage Group SE (hereinafter “Cantourage”, ISIN: DE000A3DSV01) and Canadian cannabis producer LOT420 are deepening their partnership following LOT420’s successful EU-GMP certification. Cantourage once again supported the certification process as sponsor and will benefit from exclusive access to LOT420’s popular cannabis products in Europe for the coming years. Following the successful EU-GMP certification of cultivation partner Green Karat just a few weeks ago, this latest milestone further demonstrates Cantourage’s regulatory expertise and strengthens its supply chain across the company’s European target markets.

Based southeast of Montreal, LOT420 is an established premium supplier in the European medical cannabis market. The producer specializes in high-quality craft cannabis, focusing on small-batch cultivation of non-irradiated cannabis flowers and cultivation techniques refined over many years. Cantourage first introduced LOT420’s products to the European market in 2023, where the company has since established itself as one of the most respected brands in the medical cannabis sector.

With LOT420’s EU-GMP certification, Cantourage is further strengthening its value chain and creating additional opportunities for importing dried cannabis flowers from Canada. As a result, LOT420’s premium flowers will be able to reach European pharmacies even faster after harvest. At the same time, shifting processing steps to EU-GMP-certified cultivation partners enables a more efficient cost structure, additional capacity and reduced operational risks. Cantourage is thus further expanding its position as a strategic partner for international premium producers seeking access to the European market.

“Together with us, LOT420 has become another long-standing partner to successfully achieve EU-GMP certification. The strong demand for LOT420’s products demonstrates just how important access to high-quality brands and products is to our market position. At the same time, by supporting our partners in obtaining certification, we are laying the foundation for more efficient supply chains, regulatory stability and further growth. This is another clear validation of our business model of enabling international cannabis producers to enter the European market as their regulatory and commercial partner,” says Philip Schetter, CEO of Cantourage Group SE.

Cantourage remains committed to systematically expanding its international network of EU-GMP-certified premium producers. The combination of strong partnerships, regulatory expertise and an increasingly flexible supply chain provides a solid foundation for further strengthening the company’s competitive position in Europe.

About Cantourage

Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards. The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).

Hamburg, Germany, October 29, 2026 – Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English.

Webcast details

Date:  Thursday, November 5, 2026

Time:  2.00 pm CET (1.00 pm GMT, 8.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: www.evotec.com.

Conference call details

To join the conference call, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialing in via phone is available under this link.

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec’s global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

Dräger with higher net sales and earnings in the first nine months of 2026

• Order intake noticeably increased
• Net sales growth in both divisions
• EBIT increased by almost half – positive one-off effects from customs refunds

Lübeck – Drägerwerk AG & Co. KGaA increased its order intake by approximately EUR 79 million to around EUR 2,674 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Net sales rose by approximately EUR 110 million to around EUR 2,454 million (9 months 2025: EUR 2,343.5 million). Earnings before interest and taxes (EBIT) went up by approximately EUR 35 million to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin improved to 4.6 percent (9 months 2025: 3.3 percent). EBIT included one-off effects from customs refunds.

“Demand for our ‘Technology for Life’ increased noticeably in the first nine months of 2026, and net sales also rose sharply. Earnings before interest and taxes were significantly above the prior-year level – due to the refund of U.S. customs paid in the prior year, but also thanks to the strong operating performance,” says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. “We are confident that we will achieve our annual targets.”

Order intake continues to rise
Group order intake rose by 3.6 percent (net of currency effects) to EUR 2,673.5 million in the first nine months of 2026 (9 months 2025: EUR 2,594.1 million). Germany was the largest growth driver, with a significant increase of around 15 percent. Demand also grew in the Europe, Middle East, and Africa (EMEA) and Asia-Pacific (APAC) regions. The Americas region recorded a decline. The main reason for this was the high prior-year level: In the second quarter of 2025, Dräger had received a major order for hospital infrastructure systems from Mexico.

In the medical division, order intake decreased by 3.5 percent (net of currency effects) to EUR 1,430.7 million (9 months 2025: EUR 1,495.5 million). Excluding the major order in the prior year, it would have remained almost stable (net of currency effects).

In the safety division, order intake increased significantly by 13.1 percent (net of currency effects) to EUR 1,242.8 million (9 months 2025: EUR 1,098.6 million). All regions and all product areas contributed to this development.

Strong net sales growth in both divisions
Group net sales increased by 5.3 percent (net of currency effects) to EUR 2,453.9 million in the first nine months of 2026 (9 months 2025: EUR 2,343.5 million). In the medical division, net sales increased by 4.4 percent (net of currency effects) to EUR 1,367.0 million (9 months 2025: EUR 1,322.3 million). In the safety division, net sales increased by 6.5 percent (net of currency effects) to EUR 1,087.0 million (9 months 2025: EUR 1,021.2 million).

Earnings significantly above the prior year
EBIT rose by almost half to EUR 111.8 million (9 months 2025: EUR 77.1 million). The EBIT margin also improved significantly by 1.3 percentage points to 4.6 percent (9 months 2025: 3.3 percent).

EBIT for the first nine months included one-off effects of EUR 27.9 million from customs refunds. Of this amount, EUR 7.8 million was attributable to the second quarter and EUR 20.1 million to the third quarter. Part of these refunds – a total of EUR 3.8 million – relates to customs expenses from the current fiscal year and is therefore earnings-neutral. At the same time, customs expenses of EUR 25.8 million were incurred in the U.S. in the current year, which are nonrefundable under current law.

The gross margin benefited from the customs refunds by around one percentage point. It increased by 1.7 percentage points to 46.8 percent (9 months 2025: 45.1 percent). Functional expenses in the first nine months of 2026 were 5.6 percent higher than the prior-year figure. The main drivers were personnel, logistics, and IT costs.

Business performance in the third quarter
In the third quarter, order intake increased by 7.0 percent (net of currency effects) to EUR 926.2 million (Q3 2025: EUR 856.1 million). The medical division recorded a decline of 3.0 percent (net of currency effects) to EUR 474.3 million (Q3 2025: EUR 484.7 million) due to weaker demand in the EMEA region. Demand in the Middle East declined significantly due to the ongoing Iran conflict. In the safety division, order intake increased by 20.2 percent (net of currency effects) to EUR 451.9 million (Q3 2025: EUR 371.4 million), thanks to good performance in all regions. Germany was the largest driver, with above-proportional growth of around 59 percent (net of currency effects), due in particular to a major order in the defense business.

Dräger’s net sales rose by 1.0 percent (net of currency effects) to EUR 850.8 million (Q3 2025: EUR 833.3 million). The gross margin increased by 1.8 percentage points to 47.5 percent (Q3 2025: 45.6 percent). EBIT came to EUR 48.0 million (Q3 2025: EUR 56.7 million). The EBIT margin amounted to around 5.6 percent (Q3 2025: 6.8 percent).

Forecast for 2026
For the current fiscal year, Dräger continues to expect an increase in net sales of 2.0 to 6.0 percent (net of currency effects) and an EBIT margin of 6.0 to 8.0 percent.

Further information is available in the financial report at www.draeger.com.

Disclaimer
This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company’s knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company’s influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Information on the financial indicators used (incl. alternative performance measures) can be found on our corporate website www.draeger.com in our Investor Relations section.

NVision Unveils First Manufacturable Molecular Qubit, Breakthrough Validated in Peer-Reviewed Nature Paper

Partners with HyperLight to integrate thin-film molecular qubits onto advanced photonic integrated circuits, paving the way for a new architecture that delivers quantum computing at scale

Summary:

• Announces publication of landmark peer-reviewed research in Nature validating the first individually addressable organic molecular qubit with photonic interface.
• Advances a quantum computing architecture that combines compatibility with standard silicon foundry manufacturing with photonic connectivity to enable quantum computing at scale.
• Establishes a strategic partnership with HyperLight to integrate thin-film molecular qubits directly onto advanced photonic integrated circuits. 

ULM, Germany – October 28, 2026 – NVision, a quantum technology company, announced the publication of landmark peer-reviewed research in Nature and a strategic partnership with HyperLight Corporation (“HyperLight”), an industry leader in thin-film lithium niobate (TFLN) photonics. The companies will integrate NVision’s thin-film molecular qubits directly onto advanced photonic integrated circuits (PICs). Together, these milestones establish a practical path to quantum computing at scale, using photonic connectivity to link quantum resources within and across processors. This opens a path toward millions of qubits on chips compatible with standard foundry manufacturing.

The Nature publication, A Single-Molecule Spin-Photon Interface, confirms the first ever individually addressable organic molecular spin-photon interface, which is the key ingredient for connecting stationary qubits with photons. Until now, molecular spins could not be individually and coherently controlled, preventing them from serving as true qubits. That barrier has now been broken: the core building block can be controlled at the single-molecule level. This opens a new path to scale, where molecular qubits can be deposited as thin films, much like OLED materials, directly on top of PICs, turning established photonic chip technology into a platform for scaling quantum computers.

“This proves what we’ve long believed: that organic chemistry offers a fundamentally better building block for quantum,” said Dr. Sella Brosh, CEO of NVision. “For years, the industry has been locked in a hardware race using modalities that would require decades and multi-billion-dollar proprietary fabrication facilities to achieve scale. With the creation of the world’s first manufacturable organic qubit, we now enter quantum’s molecular era, establishing a new architecture based on photonic connectivity from the get-go, with a clear path to scale through existing foundry infrastructure.”

Alongside the Nature publication, NVision announced a strategic partnership with HyperLight, a global leader in TFLN electro-optic PICs for high-bandwidth environments such as AI data centers, telecom and metro networks. The collaboration will integrate NVision’s molecular qubits as a thin film that can be deposited directly onto photonic chips, extending HyperLight’s TFLN Chiplet™ technology further into quantum applications. 

“Integrating NVision’s breakthrough molecular qubits onto our PICs unlocks a compelling path for scalable quantum hardware while showcasing the capabilities and versatility of HyperLight’s TFLN technology,” said Kevin Luke, co-founder and Head of Custom Development at HyperLight. “Photonic interconnectivity is essential for scaling quantum processors, and combining our optical chip infrastructure with manufacturable molecular thin films allows us to deliver high-density, chip-scale quantum connectivity that leverages decades of investment in semiconductor fabrication.”

The milestone directly advances NVision’s Photonic Integrated Quantum Circuits (PIQC) platform from foundational physics into commercial hardware development. Following initial chip deliveries from foundry partners, NVision is targeting a live demonstration of on-chip performance on PICs by the end of 2026. The company’s long-term commercial roadmap targets scaling to 1,000 physical qubits, progressing toward 1,000 logical, fault-tolerant qubits on chip by 2030 housed within a deployable data-center form factor.

Unlike monolithic quantum architectures that force qubits into tight physical proximity, which creates severe crosstalk, control complexity and thermal bottlenecks, NVision’s Photonic Integrated Quantum Circuit (PIQC) architecture uses optical links to decouple qubits from local spatial constraints. The engineered carbene molecules function at accessible cryogenic temperatures (2K – 4K) and emit photons natively at precise optical frequencies, enabling direct intra-chip and inter-chip quantum entanglement.

“Chemistry gives us a design freedom that semiconductor-based qubits, such as in silicon, simply do not have. By addressing quantum design at the molecular level, we can tune the performance that matters most, including quantum memory, gate speed and photon emission, within a single molecule,” said Dr. Ilai Schwartz, CTO of NVision. “Because our qubits interact directly with light from the start, we achieve connectivity without proximity, making photonic networking a foundational capability of our platform rather than something we have to add later.”

To achieve this milestone, NVision combined large-scale computational screening with targeted synthesis, evaluating more than 150 candidate molecules, out of which 40 were synthesized in the laboratory. The resulting carbene system is engineered to interface directly with photons, making photonic connectivity a practical building block for scalable architectures. Crucially, the platform tolerates up to 70% photon loss, enabling reliable operation with standard silicon photonics rather than requiring ultra-low-loss, specialized optical infrastructure.

First prototype integrated chips resulting from the collaboration are expected in Q4 2026. For detailed technical specifications, architectural white papers, and access to the peer-reviewed Nature study (DOI: 10.1038/s41586-026-11147-6), read  Designed, not Discovered: A Molecule Built to Be a Qubit.

Prineha Narang, Partner, DCVC:

“At DCVC, we’re excited to back NVision because we believe its molecular qubit platform has the potential to accelerate the roadmap for quantum computing as a whole. Using molecules as the building blocks of quantum hardware is a visionary approach, one that could make qubits easier to manufacture, scale, and industrialize. This is the kind of innovation that could bring us closer to realizing quantum computing’s promise, including the discovery of new materials and molecules.”

Peter Barrett, Co-Founder and General Partner, Playground Global:

“The ability to read and write spin states with light is a breakthrough in our ability to control the quantum nature of nature. NVision brings manufacturability and the design freedom of chemistry to quantum computing, with molecular qubits that could be integrated directly onto photonic chips. It opens a remarkable possibility: designing molecules to build computers that can, in turn, help us design entirely new forms of matter.” 

Avi Eyal, Managing Partner, Entrée Capital:

“From the start, the NVision team chose to solve quantum’s scaling problem at the molecular level rather than brute-force it with ever-larger fabrication plants. The announcement today puts NVision among the few companies with a credible, manufacturable path to quantum computing at scale. Few teams anywhere combine this depth in quantum physics, organic chemistry and photonics, and we’re proud to support them as they move from foundational science to commercial hardware.”

Christian Reitberger, Founding Partner, Matterwave Ventures:

“It is exciting to see NVision’s quantum metabolic imaging work being complemented by a computing modality that will benefit rational drug design, thus enabling a fast design to metabolic testing loop. That the carbene-photon interface can be realized on existing commercial PIC technology is crucial for a capital efficient path towards a useful computing system.”

Marco Allegretti, Senior Partner of AI Fund at CDP Venture Capital:

“This important milestone reflects both the strength of NVision’s vision and the outstanding execution demonstrated by its team. The publication in Nature and the partnership with HyperLight mark a significant validation of the company’s technological journey and further strengthen the investment thesis that convinced us to support NVision from its earliest stages.”

Dr. Itamar Sivan, Co-Founder and CEO, Quantum Machines:

“NVision’s achievement introduces an exciting new building block for quantum computing, bringing together molecular qubits and photonic connectivity with a vision for scale. Quantum Machines’ control platform brings these elements together, helping turn pioneering science into working quantum systems. We’re delighted to contribute to this milestone and to work alongside NVision as they build toward scalable quantum computers.”
 

About NVision Quantum Technologies 

NVision is a full stack quantum technology company focused on healthcare, with deep expertise in engineering and controlling the quantum properties of organic molecules. This approach underpins both its POLARIS platform, which enables real-time measurement of metabolism on standard MRI systems, and its quantum computing platform, Photonic Integrated Quantum Circuits (PIQC, pronounced “Pixie”). Together, these capabilities are helping bridge the gap between understanding disease and delivering effective therapies. Founded in 2015 and headquartered in Ulm, Germany, NVision is backed by Playground Global, DCVC, Entrée Capital, Matterwave/b2venture, Lauder Partners, Pathena Investments, The European Investment Bank and others. Learn more at nvision-quantum.com.

About HyperLight

HyperLight delivers high-performance integrated photonics solutions based on thin-film lithium niobate technology. The company combines the electro-optic advantages of TFLN with scalable manufacturing, test, and integration to enable next-generation optical engines for AI data centers, telecom and metro networks, and emerging photonics markets.

Media Contact:

For high-resolution images or any other inquiries, please contact press@nvision-quantum.com

Braunschweig, Germany, 28 October 2026. Eckert & Ziegler Therapeutics GmbH, wholly owned subsidiary of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Actinium-225 (Ac-225). The certification by the competent German authority confirms that production meets the stringent requirements of Good Manufacturing Practice (GMP) and facilitates the use of the radioisotope for the investigational treatment of patients.

Actinium-225 is widely regarded as one of the most promising alpha emitters for use in targeted radiopharmaceutical applications. This is reflected in both the increasing number of clinical trials investigating this radionuclide and the advancement of clinical programs into later-stage development.

“This regulatory milestone is the decisive step that turns our production capability into a supply commitment the field can build their clinical and commercial programs on,” said Dr. Gunnar Mann, Member of the Executive Board and responsible for Operations at Eckert & Ziegler’s Medical Segment. “We have quickly moved from first production runs in our upscaled process to GMP grade routine manufacturing. This is what improving supply security looks like in practice.”

The overall production route uses cyclotron-based irradiation of Radium-226 (Ra-226) at the Řež facilities of the Czech Academy of Sciences’ Nuclear Physics Institute (Ústav jaderné fyziky, “UJF”). Afterwards the irradiated material is processed at Eckert & Ziegler’s Braunschweig site to obtain GMP grade Ac-225. Production activities at both sites are supported by custom-engineered hot cell systems from Isotope Technologies Dresden GmbH, Eckert & Ziegler’s hot cell division.

The proprietary process set up by Eckert & Ziegler ensures that the cyclotron-based production of Ac-225 results in an isotopic profile with long-lived impurities such as Actinium-227 and Thorium-229 kept to a minimum, thereby meeting the expectations of nuclear medicine physicians and radiopharmacists alike.

Secured access to Radium-226
Accessing Ra-226 as the precursor material is one of the principal bottlenecks in global Ac-225 production. To alleviate the pressure on its supply chain, Eckert & Ziegler has integrated the repurposing of Ra-226 legacy sources into its sourcing strategy. Additionally, the production method recovers unconverted Ra-226 after irradiation and reintroduces it to the process, allowing the material to be used across multiple cycles. This helps reduce dependency on constrained global Ra-226 inventories while limiting radioactive waste, contributing to more predictable output volumes and costs for both radioisotope supply and CDMO programs.

Capacity expansion in Asia and North America
The newly opened production facility of Eckert & Ziegler’s joint venture Qi Kang Medical Technology (Changzhou) Co., Ltd. in Jintan, China is intended to become the first site in the country dedicated to the production of Ac-225 on a commercial scale. This second phase is planned to be realized after initial operations start in early 2027.
In addition, further capacity expansion can be considered at Eckert & Ziegler’s established radiopharmaceutical manufacturing site near Boston, MA, USA, as well as in Germany, to support the future commercial supply of Ac-225-based medicinal products.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,100 employees, is THE leading independent radioisotope supplier and a specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

Preclinical program will evaluate Topadur’s proprietary, locally acting compounds, including clinical-stage TOP-N53, which target key disease processes in dystrophic Epidermolysis bullosa, a rare and debilitating genetic skin disorder

Munich, Germany, and Schlieren-Zurich, Switzerland, 28 October 2026 – DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

The program will evaluate Topadur’s clinical-stage compound TOP-N53 together with additional selected small molecules from its proprietary DualTOP® platform. The compounds will be investigated in in vitro and in vivo models addressing two major and interconnected challenges in DEB: impaired wound healing and fibrosis. The studies will be conducted in collaboration with the Medical Center – University of Freiburg, Germany, and EB Research Institute GmbH in Salzburg, Austria.

“People living with dystrophic EB face severe complications that extend far beyond chronic wounds,” said Prof. Hubert Trübel, MD, MBA, Managing Director of ReadOn Therapeutics, a DEBRA Research spinout. “Through our investment in Topadur, we are supporting the development of locally acting therapies that target several interconnected aspects of the disease. We see this as an important step toward exploring new approaches that go beyond wound management alone.”

“DEBRA Research brings deep expertise in EB and a strong understanding of the needs of people living with this devastating disease. Their support as an investor and partner in this program is an important endorsement of our approach and underscores the broader potential of our DualTOP® platform in indications with significant unmet medical needs,” said PD Dr. Matthias Schäfer, CEO of Topadur Pharma AG.

EB comprises a group of rare genetic conditions characterized by extremely fragile skin that is prone to blistering and wounds, even from minor friction or trauma. In DEB, mutations in the COL7A1 gene impair collagen VII, resulting in recurrent skin lesions within the dermis. Repeated cycles of injury and repair can lead to chronic wounds, progressive fibrosis, scarring, and severe functional impairment. Despite recent advances in wound treatment, there is still a significant need for therapies addressing these interconnected disease processes.

Topadur’s DualTOP® platform comprises locally acting small molecules designed to modulate complementary signalling pathways involved in tissue repair and disease progression. TOP-N53, Topadur’s lead asset, has demonstrated wound-healing activity in preclinical models and increased local skin perfusion in a first-in-human Phase 1 study, where it was well tolerated. It is currently in Phase 2a clinical development for digital ulcers in systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA. Across the broader DualTOP® platform, Topadur compounds have also demonstrated anti-fibrotic activity in preclinical models. The DEB program will investigate these complementary properties in disease-relevant models.

About Topadur Pharma AG

Topadur Pharma AG, based in Schlieren-Zurich, Switzerland, is a clinical-stage biopharmaceutical company developing locally acting small-molecule therapies. Its proprietary DualTOP® platform targets the cGMP signalling pathway, a central regulator of vascular regeneration and tissue repair. Building on this technology, the company is advancing a pipeline of therapeutic candidates for age- and disease-related conditions with significant unmet medical needs. Topadur’s lead candidate, TOP-N53, is undergoing Phase 2a clinical evaluation for the treatment of digital ulcers in patients with systemic sclerosis. In parallel, TOP-M119 is being prepared for first-in-human clinical trials targeting alopecia.

For more information, please visit www.topadur.com and follow Topadur on LinkedIn.

About DEBRA Research

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for Epidermolysis Bullosa (EB), a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation. DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving their quality of life, while striving for a future where EB is curable – a “world without EB.”

For more information, please visit www.debra-research.org and follow us on LinkedIn.

Contacts

DEBRA Research
Prof. Hubert Trübel
info@debra-research.org

Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Media inquiries

MC Services
Anne Hennecke, Dr. Johanna Kobler, Julia Bittner
+49 89 210 2280
contact@mc-services.eu
 

Disclaimer (Topadur Pharma AG)

TOP-N53 and the other compounds referred to in this press release are investigational and have not been approved by any regulatory authority. The program in dystrophic epidermolysis bullosa is at the preclinical stage; the safety and efficacy of these compounds in epidermolysis bullosa have not been established.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG (Topadur). This publication may contain certain forward-looking statements and assessments or intentions concerning Topadur and its business, including the research program described in this release. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Topadur to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. Topadur disclaims any obligation to update these forward-looking statements, assessments or intentions.